关于独立董事独立性自查情况的专项报告 根据《上市公司独立董事管理办法》《深圳证券交易所创业板股票上市规则》《深 圳证券交易所上市公司自律监管指引第2号——创业板上市公司规范运作》等要求，广 东广康生化科技股份有限公司（以下简称"公司"）董事会就公司在任独立董事彭文平、 黄志威、张志祥的独立性情况进行评估并出具如下专项意见： 经核查独立董事彭文平、黄志威、张志祥的任职经历以及签署的相关自查文件，上 述人员未在公司担任除独立董事以外的任何职务，也未在公司主要股东公司担任任何职 务，与公司以及主要股东之间不存在利害关系或其他可能妨碍其进行独立客观判断的关 系，因此，公司独立董事符合《上市公司独立董事管理办法》《深圳证券交易所创业板 股票上市规则》《深圳证券交易所上市公司自律监管指引第2号——创业板上市公司规 范运作》中对独立董事独立性的相关要求。 广东广康生化科技股份有限公司 董事会 2025 年 4 月 18 日 1 / 1 广东广康生化科技股份有限公司董事会 ...

Financial Performance - The company's revenue for Q1 2025 was CNY 187,242,875.58, representing a 5.16% increase compared to CNY 178,058,819.17 in the same period last year[4] - Net profit attributable to shareholders decreased by 3.17% to CNY 17,109,527.99 from CNY 17,670,252.56 year-on-year[4] - The company's basic earnings per share decreased by 4.17% to CNY 0.23 from CNY 0.24 year-on-year[4] - Net profit for the current period was ¥17,007,426.37, slightly down from ¥17,638,311.26 in the previous period, representing a decrease of 3.6%[19] - Earnings per share (EPS) for the current period was ¥0.23, compared to ¥0.24 in the previous period[20] Cash Flow - The net cash flow from operating activities improved significantly, reaching CNY 4,224,156.30, a 382.43% increase from a negative cash flow of CNY -1,495,654.65 in the previous year[4] - Cash inflow from operating activities totaled ¥133,278,454.70, significantly higher than ¥92,707,705.87 in the previous period, marking an increase of 43.7%[22] - The net cash flow from operating activities was 4,224,156.30, a significant improvement from the previous period's negative cash flow of -1,495,654.65[23] - Cash inflow from investment activities reached 958,147,125.93, up from 580,638,710.89 in the previous period[23] - The net cash flow from investment activities was -56,833,082.45, a decline from the previous period's positive cash flow of 58,471,234.40[23] - Cash inflow from financing activities amounted to 136,296,628.05, compared to 101,116,615.87 in the prior period[23] - The net cash flow from financing activities increased to 61,959,260.62 from 3,810,123.30 in the previous period[23] Assets and Liabilities - Total assets increased by 1.29% to CNY 2,011,100,312.28 compared to CNY 1,985,396,036.66 at the end of the previous year[4] - Total current assets increased to CNY 1,086,819,116.31 from CNY 1,063,088,386.12, reflecting a growth of approximately 2.3%[15] - Total liabilities decreased from CNY 521,263,307.26 to CNY 497,432,448.74, a reduction of approximately 4.5%[15] - Total liabilities increased to ¥669,113,027.68 from ¥661,718,705.69, showing a growth of 1.9%[16] - Total equity attributable to shareholders of the parent company rose to ¥1,341,025,065.38 from ¥1,322,613,010.13, an increase of 1.4%[16] Research and Development - The company reported a significant increase in research and development expenses, which rose by 74.34% to CNY 763.60 from CNY 437.99 in the same period last year[9] - Research and development expenses rose to ¥7,635,984.13, up 74.5% from ¥4,379,916.17 in the previous period, indicating a strong focus on innovation[18] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 8,501[11] Financial Management - The company experienced a 67.23% increase in trading financial assets, amounting to CNY 45,201.59, due to cash management using idle raised funds[8] - Trading financial assets significantly increased to CNY 452,015,943.14 from CNY 270,295,332.05, representing a growth of approximately 67.2%[14] - Financial expenses increased to ¥3,504,779.31, compared to ¥1,394,119.37 in the previous period, reflecting higher interest costs[19]

Financial Performance - The company reported a plan not to distribute cash dividends, issue bonus shares, or increase capital from reserves[7]. - The company's operating revenue for 2024 reached ¥723,480,846.94, representing a 46.15% increase compared to ¥495,011,431.63 in 2023[18]. - Net profit attributable to shareholders for 2024 was ¥34,681,288.66, up 15.33% from ¥30,071,413.11 in 2023[18]. - The net profit attributable to shareholders after deducting non-recurring gains and losses decreased by 11.45% to ¥23,052,118.57 from ¥26,034,191.14 in 2023[18]. - The total assets at the end of 2024 were ¥1,985,396,036.66, an increase of 8.43% from ¥1,831,102,296.46 at the end of 2023[18]. - The basic earnings per share for 2024 was ¥0.47, a slight increase of 2.17% from ¥0.46 in 2023[18]. - The company reported a cash flow from operating activities of ¥14,344,838.53, which is a 14.79% increase from ¥12,496,503.91 in 2023[18]. - The company experienced a significant decline in net profit in the second quarter, reporting a loss of ¥6,916,400.18 attributable to shareholders[21]. - The company received government subsidies amounting to ¥1,324,480.88 in 2024, down from ¥3,222,499.95 in 2023[24]. Risk Factors - The company faces major risks including raw material price fluctuations, market competition, safety production risks, environmental protection risks, and exchange rate fluctuations[6]. - The company emphasizes the importance of risk awareness for investors regarding future plans and performance forecasts[6]. - The company faces risks from raw material price fluctuations, with strategies to enhance strategic procurement management and optimize supply chain management to mitigate impacts[134]. - The company faces foreign exchange risk due to overseas sales primarily denominated in USD, which could significantly impact performance with increased international sales[139]. Market Trends - The global pesticide market is expected to grow due to increasing food demand driven by population growth, with the global population projected to reach nearly 8.2 billion by mid-2024[28]. - Climate change is exacerbating pest and disease issues, with a 10%-25% increase in crop losses due to pests for every 1°C rise in temperature, highlighting the ongoing demand for pesticide products[29]. - The global pesticide market is currently in a destocking phase, with significant price declines observed due to high interest rates and supply chain adjustments[30]. - In 2024, China's pesticide export volume is projected to reach 3.1761 million tons, a 28.82% increase from 2.4656 million tons in 2023, while export value is expected to hit $8.999 billion, up 11.28% from $8.087 billion[36]. Product Development and Innovation - The company has obtained 125 pesticide product registration certificates and 39 production licenses, showcasing its strong product development capabilities[40]. - The company focuses on a "differentiated and niche" competitive strategy, developing high-margin products with strong market potential[38]. - The company has innovated clean production processes for key products, aligning with national agricultural development policies[40]. - The company has established a strict and standardized production management system, obtaining certifications for quality, occupational health and safety, and environmental management[41]. - The company is actively pursuing new product development to enhance its competitive edge in the agricultural chemicals sector[49]. Corporate Governance - The board of directors confirmed the accuracy and completeness of the annual report, with all members present for the meeting[6]. - The financial report is guaranteed to be true, accurate, and complete by the company's responsible persons[5]. - The company has held two shareholder meetings during the reporting period, adhering strictly to legal and regulatory requirements[145]. - The board of directors consists of 7 members, including 3 independent directors, ensuring compliance with governance standards[147]. - The company has established an independent financial accounting system, enabling it to make autonomous financial decisions[152]. Environmental Compliance - The company strictly adheres to various environmental protection laws and industry standards, including the "Water Pollution Prevention Law" and "Air Pollution Prevention Law"[197]. - The company's wastewater discharge includes ammonia nitrogen at 4.158 mg/L, which is below the limit of 10 mg/L, and chemical oxygen demand at 18.986 mg/L, below the limit of 90 mg/L[199]. - The company has established online monitoring systems for major pollutants at discharge points to ensure compliance with environmental standards[200]. - The company has implemented a principle of "clear sewage diversion" and continuously optimizes wastewater collection and treatment systems[200]. Research and Development - The company invested 38.83 million yuan in R&D, accounting for 5.37% of operating revenue, enhancing innovation and technical support for business development[65]. - The company increased its R&D personnel from 68 in 2023 to 80 in 2024, representing a growth of 17.65%[94]. - R&D investment amounted to ¥38,829,391.03 in 2024, accounting for 5.37% of operating revenue, slightly down from 5.47% in 2023[94]. - The company is conducting small-scale tests for new formulation products, aiming to develop economically viable new formulations and enhance market competitiveness[92]. Financial Management - The company has established a comprehensive internal control system to manage risks and ensure effective operations, with no significant omissions identified[190]. - The internal control evaluation report will be fully disclosed on April 18, 2025, covering all units and business areas of the company[192]. - The company’s internal control system is designed to prevent significant misstatements in financial reporting and is regularly evaluated for effectiveness[190]. - The company has not implemented any employee stock ownership plans or other incentive measures during the reporting period[188]. Strategic Planning - The company aims to implement a "one chain, multiple heads" industrial chain structure to enhance its competitive advantage and cost efficiency in the agricultural chemical sector[126]. - The company plans to focus on core products, industrial chain construction, and cost reduction in its 2025 operational plan[128]. - The company plans to enhance its digital marketing strategy, aiming for a 50% increase in online sales channels[8]. - The company is exploring opportunities for market expansion and potential acquisitions to strengthen its position in the industry[49].

广康生化（300804）公告，2024年营业收入7.23亿元，同比增长46.15%。归属于上市公司股东的净利润 3468.13万元，同比增长15.33%。基本每股收益0.47元/股，同比增长2.17%。公司计划不派发现金红利， 不送红股，不以公积金转增股本。 ...

证券代码：300804 证券简称：广康生化 公告编号：2025-002 广东广康生化科技股份有限公司 关于近期经营情况的自愿性信息披露公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 广东广康生化科技股份有限公司（以下简称"公司"）为便于广大投资者全 面了解公司经营情况，增强投资信心，现结合投资者关注的问题，将公司近期经 营情况公告如下： 一、美国加征关税对公司的影响 近日，美国政府发布关于所谓"对等关税"的行政令，宣布美国对贸易伙伴 加征10%的"最低基准关税"，并对某些贸易伙伴征收更高关税，引发市场高度 关注。 公司在全球市场布局中对单一国家或地区的依赖度较低，对美国客户的直接 销售额占总收入的比例较低。公司在产品选择上一直实行"差异化、小众化"的 竞争策略，主要产品可替代性弱，且由于国际市场对中国原药的依赖性强，本次 美国关税调整对公司生产经营不会产生重大不利影响。 公司将密切关注相关政策变化，与客户保持紧密沟通，通过协商定价机制等 举措，共同分担潜在成本压力。同时，公司将扩大内销以及开拓新兴市场，提升 公司在全球化布局中的抗风险能力。 二、克菌丹与 ...

培训情况报告 华泰联合证券有限责任公司关于 广东广康生化科技股份有限公司持续督导期 2024年培训情况报告 深圳证券交易所： 华泰联合证券有限责任公司（以下简称"华泰联合证券"、"保荐机构"）作 为广东广康生化科技股份有限公司（以下简称"广康生化"、"公司"）首次公开 发行股票并在创业板上市的保荐机构，根据《深圳证券交易所上市公司自律监管 指引第 13 号——保荐业务》《深圳证券交易所创业板股票上市规则》和《深圳证 券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》等法规和 规则的相关规定以及广康生化的实际情况，认真履行保荐机构应尽的职责，对广 康生化的董事、监事、高级管理人员、中层以上管理人员及上市公司控股股东和 实际控制人等相关人员进行了有计划、多层次的后续培训，所培训的内容严格按 照中国证券监督管理委员会及深圳证券交易所有关持续督导的最新要求进行。 2025 年 2 月 28 日，华泰联合证券相关人员按照《深圳证券交易所上市公司 自律监管指引第 13 号——保荐业务》的要求完成了对广康生化董事、监事、高 级管理人员、中层以上管理人员及上市公司控股股东和实际控制人等相关人员的 持续培训工作 ...

现场检查报告 | 2.是否在股票上市后六个月内建立内部审计制度并设立内部审计 | √ | | | --- | --- | --- | | 部门（如适用） | | | | 3.内部审计部门和审计委员会的人员构成是否合规（如适用） √ | | | | 4.审计委员会是否至少每季度召开一次会议，审议内部审计部门提 √ | | | | 交的工作计划和报告等（如适用） | | | | 5.审计委员会是否至少每季度向董事会报告一次内部审计工作进 √ | | | | 度、质量及发现的重大问题等（如适用） | | | | 6.内部审计部门是否至少每季度向审计委员会报告一次内部审计 | | | | √ 工作计划的执行情况以及内部审计工作中发现的问题等（如适用） | | | | | √（根 据相关 | | | 7.内部审计部门是否至少每季度对募集资金的存放与使用情况进 | 规定每 | | | 行一次审计（如适用） | 半年进 | | | | 行 | 一 | | | 次） | | | 8.内部审计部门是否在每个会计年度结束前二个月内向审计委员 | √ | | | 会提交次一年度内部审计工作计划（如适用） | | | | √（202 ...

证券代码：300804 证券简称：广康生化 公告编号：2024-041 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 广东广康生化科技股份有限公司（以下简称"公司"）于2024年11月13日收 到华泰联合证券有限责任公司出具的《华泰联合证券有限责任公司关于更换广东 广康生化科技股份有限公司首次公开发行股票并在创业板上市持续督导保荐代 表人的函》。 公司首次公开发行股票于2023年6月27日在深圳证券交易所创业板上市。华 泰联合证券有限责任公司作为公司首次公开发行股票并在创业板上市的保荐机 构，原指定张新星先生、刘恺先生担任公司的保荐代表人，负责公司的保荐和持 续督导工作，持续督导期至2026年12月31日止。 现刘恺先生因工作变动从华泰联合证券有限责任公司离职，不再继续担任公 司持续督导工作的保荐代表人。为保证持续督导工作的有序进行，华泰联合证券 有限责任公司委派胡轶聪先生（简历附后）接替刘恺先生履行持续督导工作职责。 本次变更后，公司首次公开发行股票并在创业板上市项目的持续督导保荐代 表人为张新星先生和胡轶聪先生。 公司董事会对刘恺先生在担任公司保荐代表人 ...

证券代码：300804 证券简称：广康生化 公告编号：2024-039 广东广康生化科技股份有限公司 关于延期归还闲置募集资金并继续用于暂时补充流 动资金的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 广东广康生化科技股份有限公司（以下简称"公司"）于2024年10月24日召 开第三届董事会第二十五次会议及第三届监事会第十六次会议，审议通过了《关 于延期归还闲置募集资金并继续用于暂时补充流动资金的议案》，同意公司在保 证募集资金投资项目（以下简称"募投项目"）的资金需求以及募集资金使用计 划正常进行的前提下，延期归还闲置募集资金人民币10,000.00万元并继续用于暂 时补充流动资金，使用期限为自原到期之日即2024年11月20日起延长12个月，到 期前将归还至募集资金专户。现将有关情况公告如下： 一、募集资金的基本情况 经中国证券监督管理委员会《关于同意广东广康生化科技股份有限公司首次 公开发行股票注册的批复》（证监许可[2023]1008 号）同意注册，公司首次公 开发行人民币普通股 1,850.00 万股,每股发行价格为 42.45 元/股，募集 ...

证券代码：300804 证券简称：广康生化 公告编号：2024-038 广东广康生化科技股份有限公司 第三届监事会第十六次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 一、监事会会议召开情况 2、审议通过《关于延期归还闲置募集资金并继续用于暂时补充流动资金的议案》 二、监事会会议审议情况 1、审议通过《关于<2024 年第三季度报告>的议案》 公司监事会对公司编制的 2024 年第三季度报告进行了认真严格的审核，并提出 了如下的书面审核意见： （1）公司 2024 年第三季度报告的编制和审议程序符合法律、行政法规及《公司 章程》的各项规定。 （2）公司 2024 年第三季度报告的内容和格式符合中国证券监督管理委员会和深 1 圳证券交易所的规定，所包含的内容真实、准确、完整地反映了公司 2024 年第三季 度经营的实际情况，不存在任何虚假记载、误导性陈述或重大遗漏。 具体内容请见公司同日在巨潮资讯网（www.cninfo.com.cn）披露的《2024 年第 三季度报告》（公告编号：2024-040）。 表决结果：同意 3 票，反对 0 票，弃权 ...